| Objective:To observe the clinical efficacy of intravitreal injection of ranibizumab combined with or without Qihuang granule decoction in the treatment of wet age-related macular degeneration(WAMD)of liver and kidney yin deficiency type.The best corrected visual acuity(BCVA),central macular thickness(CMT),and TCM symptom scores were analyzed and compared in order to evaluate the clinical efficacy of Qihuang granule decoction combined with intravitreal injection of ranibizumab,and to provide the scientific basis for clinical treatment.Method:According to the diagnosis and exclusion criteria of this study,60 cases(60 eyes)of patients with wet age-related macular degeneration of liver and kidney yin deficiency type who attended the First Teaching Hospital of Tianjin University of TCM from February 2020 to December 2020 were screened and collected.They were randomly divided into treatment group(n = 30)and control group(n = 30).The control group was treated with intravitreal injection of ranibizumab,and the treatment group was treated with Qihuang granules in addition to the control group.The BCVA and CMT were observed and recorded of the two groups of patients before treatment,1 and 3 months after treatment.And TCM symptom scores were observed and recorded before treatment and 3 months after treatment.SPSS21.0 software was used for statistical analysis.Result:1.Baseline data: Before treatment,the two groups were compared in age,gender,eye type,BCVA,CMT and TCM symptom score.The results showed that the differences were not statistically significant(P>0.05).2.Comparison of BCVA: The BCVA of the two groups was significantly improved after treatment.There were statistically significant(P<0.05)between the two groups at each time point of treatment.There was no statistical difference between the two groups at 1 month after treatment(P>0.05),and the difference between the two groups at 3 months after treatment was statistically significant(P<0.05).3.Comparison of CMT: The CMT of the two groups decreased significantly after treatment.There were significant differences in pairwise comparison between the two groups before treatment,1 month and 3 months after treatment(P<0.05).There was no significant difference between the two groups at 1 month after treatment and 3 months after treatment(P>0.05).4.Comparison results of TCM symptom scores: Compared before and after treatment the two groups,the TCM symptom scores were significantly decreased,with statistical differences(P<0.05).Three months after treatment,the treatment group was superior to the control group in reducing TCM symptom scores,and the difference was statistically significant(P < 0.05).5.Comparison results of TCM symptom efficacy: The number of markedly effective,effective and ineffective cases were 15,11 and 4 cases in treatment group,and 8,13 and 9 cases in control group.The difference between the two groups was statistically significant(P<0.05).6.Overall curative effect comparison results: The number of effective,improved and uncured cases in the treatment group was 11,14 and 5 respectively,while that in the control group was 9,16 and 5 respectively.The difference between the two groups was not statistically significant(P>0.05).Conclusion:1.Both treatments can improve the vision of patients with WAMD of liver and kidney yin deficiency,promote the absorption of macular edema,reduce the CMT,and improve the symptoms of traditional Chinese medicine.2.Qihuang granule decoction combined with intravitreal injection of ranibizumab in the treatment of WAMD of liver and kidney yin deficiency is better than simple intravitreal injection of ranibizumab in terms of BCVA and TCM symptom score in 3 months after treatment.3.The overall curative effect of the two treatments of WAMD of liver and kidney yin deficiency is basically the same.But the Qihuang granule decoction combined with intravitreal injection of ranibizumab compared with simple intravitreal injection of ranibizumab has better curative effect on the TCM symptom. |
PDF Full Text Request